• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom partners with Fitbit for glucose-monitoring tech

September 7, 2017 By Sarah Faulkner

Fitbit, DexcomDexcom (NSDQ:DXCM) and Fitbit (NYSE:FIT) have partnered to develop and market continuous glucose monitoring technology for people with diabetes, the companies announced today.

The companies plan to integrate Dexcom’s CGM data with Fitbit’s new smartwatch, the Fitbit Ionic, so CGM users on Android or iOS devices can see their activity and glucose levels on their wrists.

“The strength of our brand and our ability to track critical health metrics continuously for up to 4+ days, coupled with Dexcom’s market leadership in CGM, present a powerful combination that we hope will help millions of people better manage their diabetes,” Fibit CEO James Park said in prepared remarks. “With Ionic, we are focused on driving positive health outcomes and more health focused tools, and this collaboration is a wonderful example of how we plan to bring that vision to our users.”

The companies hope to make their integrated product available as soon as possible in 2018 and left the option open for collaboration in the future.

“The collaboration between Dexcom and Fitbit is an important step in providing useful information to people with diabetes that is both convenient and discreet,” Dexcom president & CEO Kevin Sayer added. “We believe that providing Dexcom CGM data on Fitbit Ionic, and making that experience available to users of both Android and iOS devices, will have a positive impact on the way people manage their diabetes.”

People using Dexcom’s CGM will also be able to connect with Fitbit’s in-app community, the companies reported, where they can chat with other users.

FIT shares jumped 11% today, trading at $6.55 apiece in morning activity.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Diabetes, Drug-Device Combinations, Featured, Wall Street Beat Tagged With: DexCom Inc., fitbit

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS